[{"orgOrder":0,"company":"Fareva","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and Fareva Sign Agreement for Filling and Packaging of CureVac COVID19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fareva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fareva \/ CureVac","highestDevelopmentStatusID":"8","companyTruncated":"Fareva \/ CureVac"}]

Find Clinical Drug Pipeline Developments & Deals by Fareva

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Under the agreement, Fareva will fill & finish manufacturing of CureVac´s COVID-19 vaccine candidate, CVnCoV, a COVID-19 vaccine candidate developed by CureVac, in France.

                          Brand Name : CVnCoV

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 08, 2020

                          Lead Product(s) : CVnCoV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : CureVac

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Fareva Company Banner